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predictive value of 52% (95%CI, 37%-68%) and a negative predictive value of 97% 
(95%CI, 83%-100%). Results at 6-months follow-up were similar. Total mean medi-
cal costs per patient for PWU and CWU were € 11,302 and € 11,784 (6-months), and 
€ 12,670 and € 13,776 (12-months), respectively. The incremental costs were in favor of 
the PWU patients (€ 482 (6-months), € 1,105 (12-months)). Sensitivity analyses showed 
that the most influential parameters were hospitalization, treatment-related oper-
ations and cost of PET. ConClusions: The introduction of 18F-FDG PET in the 
diagnostic trajectory of laryngeal cancer patients with suspected recurrence after 
radiotherapy is feasible, safe and favorable from clinical and economic perspectives.
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objeCtives: Percutaneous Coronary Intervention (PCI) reduces the morbidity and 
mortality associated with Coronary Artery Disease. However up to a third of patients 
experience cardiac complications, in the year after PCI. Unplanned and emergency 
admissions are costly to the health service. This study aimed to use real-world 
administrative data to explore the costs of post-PCI complications to secondary care 
providers in England. Methods: Patients who received PCI in England between 
March and December 2011 were identified from Hospital Episode Statistic (HES) data. 
Treatment costs to secondary care were estimated using Payment by Results coding 
in the HES data set. All cause and cardiac complication related bootstrapped mean 
health-care costs were estimated at 12months, 24 months and 36 months post-PCI. 
Costs were in pound for cost year 2014. Bootstrapped t-tests were applied to com-
pare costs between those with post-PCI angina and those without. Results: 32492 
met study inclusion criteria (mean age 64 years [SD 11.8], 74% male). Bootstrapped 
cumulative mean costs to the secondary care provider were significantly higher at 
12 months in those with angina at £ 10,215, 95% CI [£10,083, £10,348] vs. £6,552, 95% 
CI [£6,503, £6,601] for those without. Significant cost differences continued to 36 
months post-PCI. These were £14,754 95% CI [£14,571, £14,936] for those with angina 
vs. £8,407, 95% CI [£8,324, £8,489] for those without. At 36 months, cardiac related 
costs, inpatient, outpatient and accident and emergency costs were significantly 
higher in those with angina (P< 0.001). ConClusions: This real-world study dem-
onstrated that patients with cardiac complications post-PCI consumed significantly 
greater secondary care resources than those without, in all cost categories and, 
across all services considered. Decision makers, and clinicians, should be aware 
that interventions and therapeutic strategies associated with lower incidence of 
cardiovascular complications could significantly reduce unplanned admissions and 
associated financial burden to the NHS.
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objeCtives: The Sanger sequencing method has been considered the gold standard 
DNA sequencing technique for approximately 30 years; however, it is now chal-
lenged by next generation sequencing (NGS). The aim of this study was to assess 
the cost entailed by Sanger DNA sequencing when it is used for somatic genet-
ics. Methods: The cost assessment was based on a multicenter study using a 
micro-costing approach. We observed Sanger sequencing sessions that started with 
the DNA sample and finished with the bio-informatics evaluation. The hospitals’ 
point of view was retained. Only direct costs were taken into account. Uncertainty 
was captured for each stage using a deterministic sensitivity analysis. All costs are 
expressed in Euros 2015. Results: Five sequencing sessions were investigated in 
four French cancer centers from February 2015 to May 2015. In total, DNA samples 
from 87 patients with 658 exons were sequenced with a mean duration of 1.815 
minutes per session. The mean total cost of sequencing was € 1,891 (SD: 1,460). 
The cost per patient was € 108 (SD: 30.36) and cost per exon was € 18 (SD: 5.52). The 
personnel (52% of total costs, SD: 0.03) and consumable (43% of total costs, SD: 0.03) 
costs represented the highest cost drivers. The bio-informatics analysis and DNA 
extraction were the costliest stages of the sequencing process (28 and 26%, respec-
tively). Total costs were highly correlated with the number of patients and exons. 
The marginal costs were € 112 and € 12 per additional patient and exon, respec-
tively. ConClusions: Our findings demonstrate the moderate costs of Sanger 
sequencing. These results can be used for further economic analyses comparing 
Sanger sequencing methods with other DNA sequencing methods such as NGS.
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objeCtives: Recent advances in novel diagnostics have led to some concerns 
on the part of purchasers as to whether the diagnostics add value or simply add 
cost. In this study we explore these concerns, using as an example the case of 
antibiotic stewardship protocols based on procalcitonin levels. The objective is to 
assess the economic impact of adopting procalcitonin testing among patients with 
suspected acute respiratory tract infection (ARI) from the perspective of a typical 
U.S. integrated delivery network (IDN) with a 1,000,000 member catchment area or 
enrollment. Methods: To conduct an economic evaluation of procalcitonin testing 
versus usual care we built a cost-impact model based on patient-level meta-analysis 
data of randomized trials. The meta-analytic data was adapted to the U.S. setting 
in reducing antibiotic exposure in adult ICU patients with sepsis, compared to cur-
rent practice in The Netherlands (NL), Germany and the UK. The reduction in anti-
biotic days as achieved by a PCT-algorithm is important given the rise in antibiotic 
resistance (ABR). Prolonged antibiotic duration affects the incidence of ABR and C. 
difficile infections (CDI), in this population amounting to 4.7% and 4.6% per hospital 
episode, respectively. We estimated the additional indirect cost savings of PCT-
testing by considering excess length of stay (LOS) due to ABR and CDI. Methods: 
Health economic consequences of a PCT-algorithm vs. current practice are analysed 
from a societal perspective using a decision tree. Input data were obtained from 
a systematic literature review and country-specific cost data sources. Effects of 
reduced duration of antibiotic therapy on ABR and CDI incidence and expected cost 
savings of a PCT-strategy were estimated for NL. Cost-effectiveness is expressed 
as incremental costs per antibiotic day avoided. Results: Excess LOS due to ABR 
and CDI is 4.6 days and 0.9 days per patient respectively. Shorter duration of anti-
biotic therapy, as achieved by a PCT-algorithm, decreases ABR and CDI incidence to 
4.5% and 3.9%, respectively. Including ABR and CDI costs in the analyses increases 
per-patient costs in both strategies, but less so for the PCT-algorithm. As a result, 
incremental cost savings of a PCT-algorithm compared to current practice increase 
with € 290 (from € 3,503 to € 3,793 per patient) when considering ABR and CDI. This 
further strengthens the dominance of the PCT-algorithm (ICER: -€ 2,231 per antibiotic 
day avoided). ConClusions: By reducing ABR and CDI incidence, a PCT-algorithm 
is expected to generate substantial indirect cost savings beyond direct health and 
economic impacts in ICU patients with sepsis.
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objeCtives: Consensus US cervical cancer screening guidelines recommend use of 
co-testing (combination Pap plus HPV testing) for women aged 30-65 years. Though 
not currently recommended by US guidelines, an HPV test was approved by the FDA 
in 2014 for primary cervical cancer screening in women 25 years and older. In this 
study, we perform clinical-economic comparisons of co-testing with genotyping 
(Co-test GT) versus primary HPV with genotyping and reflex cytology (HPV GT) for 
cervical cancer screening. Methods: A health state transition (Markov) model 
with one-year cycling was developed using epidemiologic, clinical, and economic 
data from healthcare databases and published literature. A cohort of one million 
women receiving triennial cervical cancer screening was simulated from ages 30-70 
years. Screening strategies compared HPV GT to Co-test GT. Outcomes included 
total and incremental differences in costs, invasive cervical cancer (ICC) cases, ICC 
deaths, and quality-adjusted life years (QALYs) for cost-effectiveness calculations. 
Comprehensive sensitivity analyses were performed. Results: In a simulation 
cohort of one-million 30-year-old women modeled up to age 70, the model predicted 
as many as 2,141 ICC cases and 2,040 ICC deaths could be prevented with Co-test GT 
versus HPV GT. Co-test GT demonstrated a greater number of lifetime QALYs (22,334) 
and yielded $36.1 million in savings compared with HPV GT, thereby conferring 
greater effectiveness at lower cost. Applying this model to the cross-section of 78.9 
million US women aged 30-70 years predicts nearly 150,000 ICC cases and more than 
100,000 ICC deaths could be avoided with Co-test GT versus HPV GT, representing 
cost savings of approximately $4 billion over 40 years. ConClusions: Model results 
demonstrate that co-testing with genotyping provides superior clinical and eco-
nomic outcomes when compared to primary HPV testing with genotyping and reflex 
cytology. These findings are important to US healthcare payers and women’s health 
policy advocates seeking cost-effective cervical cancer screening technologies.
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objeCtives: The aim of this study was to investigate the potential benefits and 
cost consequences of introducing 18F-Fluorodeoxyglucose Positron Emission 
Tomography (18F-FDG PET) in the diagnostic work-up of patients with suspected 
recurrent laryngeal cancer after radiotherapy. Methods: REcurrent LAryngeal car-
cinoma PET Study (RELAPS), a prospective multicenter randomized controlled trial, 
recruited 150 patients from eight head and neck cancer centers in the Netherlands 
and one center in Belgium. Two diagnostic algorithms were compared to the refer-
ence standard: (1) Conventional work-up (CWU); direct laryngoscopy with biopsy 
under general anesthesia, and (2)18F-FDG PET work-up (PWU) followed by laryn-
goscopy; only for positive or equivocal findings. Standard reference comprised his-
topathology and clinical follow-up of 6- and 12-months, respectively. Diagnostic 
performance of 18F-FDG PET and indication of unnecessary operations were effi-
cacy measures. Dutch healthcare perspective was used to obtain input parameters 
from hospital databases, patient records, literature and publicly available sources. 
Costs were expressed in 2014 Euros. Sensitivity analysis was performed. Results: 
Indication for direct laryngoscopy was classified unnecessary in 49 CWU patients 
(68%, 95%CI: 56-79) compared to 21 PWU patients (28%, 95%CI: 18-40) (p< 0.0001). 
The absolute difference between groups at 12-months was 40%. 18F-FDG PET had a 
sensitivity of 96% (95%CI, 78%-100%), specificity of 59% (95%CI, 44%-72%), a positive 
